Recombinant human interleukin-7

DRUG2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Revimmune

Conditions

HIV InfectionsMycobacterium Infections, Nontuberculous

Phase 1

Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs

CompletedNCT00099671

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2005-04-30End: 2007-04-30Updated: 2021-11-01

Phase 2

Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease

TerminatedNCT04154826

RevimmuneMycobacterium Infections, Nontuberculous

Start: 2020-11-30End: 2024-03-30Updated: 2024-04-11

Related Papers

Recombinant interleukin-7 treatment of refractory <i>Mycobacterium avium</i> complex lung disease (IMPULSE-7): a pilot phase II, single-center, randomized, clinical trial

Therapeutic Advances in Infectious Disease2025-05-101 citations

Interleukin-7 promotes HIV persistence during antiretroviral therapy.

2013-04-15200 citations